Viva Biotech to Pay $80 Million to Acquire SYNthesis in CRO Tieup

Viva Biotech of Shanghai will pay $80 million to acquire fellow drug CRO SYNthesis Med Chem ( Hong Kong ). SYNthesis is a preclinical small molecule drug discovery CRO that specializes in high-end pharmaceutical chemistry and synthetic chemistry services. The company has labs in Suzhou , Shanghai and Australia . SYNthesis' expertise is "downstream" from Viva's structure-based drug discovery services that it offers to biopharma customers. One month ago, Viva announced a $368 million deal to acquire an 80% stake in Zhejiang Langhua Pharma, a CDMO and API company. More details.... Stock Symbol: (HK: 1873) Share this with colleagues: // //